Realm Therapeutics PLC Filing with US SEC to Facilitate Nasdaq Listing (9552O)
23 May 2018 - 4:01PM
UK Regulatory
TIDMRLM
RNS Number : 9552O
Realm Therapeutics PLC
23 May 2018
Realm Therapeutics Publicly Files Registration Statement with
the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing
Ordinary Shares
MALVERN, PA, May 23, 2018 - Realm Therapeutics plc (AIM: RLM)
(the Company or Realm), a clinical stage biopharmaceutical company
focused on developing novel therapeutics in immune-mediated
diseases, today announces it publicly filed a registration
statement with the United States Securities and Exchange Commission
(the U.S. SEC) in connection with a proposed listing of American
Depositary Shares (ADSs) representing the Company's ordinary shares
on the Nasdaq Global Market (Nasdaq). The registration statement
was filed to facilitate the creation of a trading market in the
U.S. for ADSs representing the Company's ordinary shares and in
satisfaction of Realm's obligations under a registration rights
agreement entered into with investors who participated in the
Company's October 2017 private placement. The Company is not
proposing to register any new issuance of securities. The
registration statement is subject to ongoing review by the U.S.
SEC, and the proposed listing of ADSs representing the Company's
ordinary shares is subject to approval by Nasdaq. The Company's
ordinary shares will continue to be admitted to trading on the AIM
market of the London Stock Exchange.
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company
developing novel therapeutics that target the interplay between
innate and adaptive immunity. The Company's programs seek to
influence immune signaling and change the course of immune-mediated
diseases in adults and children. Realm's lead drug development
program utilizes the Company's proprietary immunomodulatory
technology for the treatment of Atopic Dermatitis, and the Company
is exploring its efficacy in other dermatology indications which
include Acne Vulgaris, and Psoriasis, as well as other therapeutic
areas. For more information on Realm Therapeutics please visit
www.realmtx.com.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
A registration statement relating to the securities described
herein has been filed with the U.S. SEC but has not yet become
effective. These securities may not be sold nor may offers to buy
be accepted prior to the time the registration statement becomes
effective. A prospectus describing the securities may be obtained
at the applicable time from Realm Therapeutics at 267 Great Valley
Parkway, Malvern, PA 19355, United States of America. For the
avoidance of doubt, such prospectus will not constitute a
"prospectus" for the purposes of Directive 2003/71/EC (and
amendments thereto, including Directive 2010/73/EU, to the extent
implemented in each relevant EU member state) and will not have
been reviewed by any competent authority in any EU member
state.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements including with respect to the creation of a trading
market for ADSs representing the Company's ordinary shares in the
United States. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements
including if the Company's registration statement is not declared
effective by the U.S. SEC or if Nasdaq fails to approve the
Company's ADS listing application. The Company cautions security
holders and prospective security holders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
RNS-RLM
Contacts:
Realm Therapeutics plc
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial Officer and Chief Operating
Officer
Outside US: +44 (0) 20 3727 1000
US: +1 212 600 1902
Argot Partners
Stephanie Marks / Susan Kim
+1 212 600 1902
FTI Consulting
Simon Conway / Mo Noonan
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer
+44 (0) 20 7496 3000
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCZXLBLVEFLBBE
(END) Dow Jones Newswires
May 23, 2018 02:01 ET (06:01 GMT)
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Apr 2024 to May 2024
Realm Thera. (LSE:RLM)
Historical Stock Chart
From May 2023 to May 2024